financetom
Business
financetom
/
Business
/
Senseonics Receives FDA Clearance for Eversense 365 Continuous Glucose Monitoring System
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Senseonics Receives FDA Clearance for Eversense 365 Continuous Glucose Monitoring System
Sep 17, 2024 5:07 AM

07:40 AM EDT, 09/17/2024 (MT Newswires) -- Senseonics ( SENS ) said Tuesday the US Food and Drug Administration has cleared the Eversense 365 continuous glucose monitoring, or CGM, system for people with Type 1 and Type 2 diabetes aged 18 years and older.

Eversense 365 provides one year of use, the company said.

Senseonics ( SENS ) said it plans to launch Eversense 365 in the US in early Q4.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved